References
1. Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma.Lancet 2017;390:85-94.
2. Pahl KS, McLean TW. Infantile Hemangioma: A Current Review. J Pediatr Hematol Oncol 2022;44:31-9.
3. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.
4. Aly MM, Hamza AF, Abdel Kader HM, Saafan HA, Ghazy MS, Ragab IA. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Eur J Pediatr 2015;174:1503-9.
5. Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and Management of Infantile Hemangioma. Pediatrics 2015;136:e1060-104.
6. Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr 2015;174:855-65.
7. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128:e259-66.
8. Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics 2016;138.
9. Leaute-Labreze C, Voisard JJ, Moore N. Oral Propranolol for Infantile Hemangioma. N Engl J Med 2015;373:284-5.
10. Tian Y, Xu DP, Tong S, Xi SL, Liu ZM, Wang XK. Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases. J Oral Maxillofac Surg 2016;74:1623-9.
11. Baselga E, Dembowska-Baginska B, Przewratil P, et al. Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma. Pediatrics 2018;142.
12. Droitcourt C, Kerbrat S, Rault C, et al. Safety of Oral Propranolol for Infantile Hemangioma. Pediatrics 2018;141.
13. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205410Orig1s000TOC.cfm. Accessed May 28, 2023.
14. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.Pediatrics 2013;131:128-40.
15. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics2019;143.
16. Leaute-Labreze C, Baselga Torres E, Weibel L, et al. The Infantile Hemangioma Referral Score: A Validated Tool for Physicians.Pediatrics 2020;145.
17. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners.J Biomed Inform 2019;95:103208.
18. Chen T, Gudipudi R, Nguyen SA, Carroll W, Clemmens C. Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. Ann Otol Rhinol Laryngol 2023;132:332-40.
19. Pattanshetti SA, Mahalmani VM, Sarma P, et al. Oral Atenolol versus Propranolol in the Treatment of Infantile Hemangioma: A Systematic Review and Meta-Analysis. J Indian Assoc Pediatr Surg2022;27:279-86.
20. Pope E, Lara-Corrales I, Sibbald C, et al. Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. JAMA Pediatr 2022;176:34-41.
21. Moehrle M, Léauté-Labrèze C, Schmidt V, Röcken M, Poets CF, Goelz R. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2013;30:245-9.
22. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics2019;143(1):e20183475.
23. Huang AH, Mannschreck D, Aggarwal P, Mahon M, Cohen BA. Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. Pediatr Dermatol 2020;37:1057-62.
24. Yang H, Hu DL, Shu Q, Guo XD. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. World J Pediatr 2019;15:546-58.
25. Giachetti A, Díaz MS, Boggio P, Posadas Martínez ML. Early propranolol treatment of infantile hemangiomas improves outcome.An Bras Dermatol 2023;98(3):310-315.
26. Léauté-Labrèze C, Frieden I, Delarue A. Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate. Pediatr Dermatol 2023;40(2):261-264.
27. Gatts JE, Rush MC, Check JF, Samelak DM, McLean TW. Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. Pediatr Dermatol 2022;39:389-93.
28. Shah SD, Baselga E, McCuaig C, et al. Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. Pediatrics 2016;137.
29. Streicher JL, Riley EB, Castelo-Soccio LA. Reevaluating the Need for Electrocardiograms Prior to Initiation of Treatment With Propranolol for Infantile Hemangiomas. JAMA Pediatr 2016;170:906-7.
30. Horii KA, Drolet BA, Frieden IJ, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol 2011;28:245-53.
31. Mahon C, McHugh K, Alband N, et al. Routine liver ultrasound screening does not alter clinical management in a cohort study of multiple cutaneous infantile haemangioma. Br J Dermatol2021;184:340-1.
32. chrome extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.accessdata.fda.gov/ drugsatfda_docs/label/2014/205410s000lbl.pdf. Accessed June 1, 2023.
33. Chang L, Ye X, Qiu Y, et al. Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China. Ann Plast Surg 2016;76:559-63.
34. Frieden IJ, Püttgen KB, Drolet BA, et al. Management of infantile hemangiomas during the COVID pandemic. Pediatr Dermatol2020;37:412-8.
35. Smithson SL, Rademaker M, Adams S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol.Australas J Dermatol 2017;58:155-9.
36. Solman L, Glover M, Beattie PE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. Br J Dermatol2018;179:582-9.
37. Chang L, Gu Y, Yu Z, et al. When to stop propranolol for infantile hemangioma. Sci Rep 2017;7:43292.
38. Fernández Faith E, Shah S, Witman PM, et al. Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma. JAMA Dermatol2021;157:566-72.
TABLE 1. Characteristics of respondents
TABLE 2. Summary of key responses
TABLE 3. Hypothetical cases and management scenarios
TABLE 1. Characteristics of respondents